A long-term care facility in Ottumwa says it has found success in treating residents that have COVID-19 with a newly approved antibody treatment.
The Good Samaritan Society has been utilizing Bamlanivimab for residents that catch the virus, demonstrate mild to moderate symptoms, and meet certain parameters such as chronic kidney disease and diabetes. Vani Tschantz of The Good Samaritan Society offered more details about the treatment.
“The antibody treatment called bamlanivimab, the first treatment for COVID-19, has been made available for any residents who qualify for such treatment,” Said Tschantz. “The goal of the infusion is to lessen the severity of the virus and prevent admissions to the hospital.“
The Food and Drug Administration says Bamlanivimab is a monoclonal antibody. Monoclonal antibodies are laboratory-produced molecules engineered to serve as substitute antibodies that can restore, enhance or mimic the immune
system’s attack on pathogens. Bamlanivimab is designed to block viral attachment and entry into human
cells, thus neutralizing the virus.
Bamlanivimab is not recommended to be used for patients that are hospitalized with Covid or are receiving oxygen therapy due to the virus.